Table 2. Human cell engraftment in adults or newborns of three strains of immunodeficient mice at 20 weeks after CD34+ cell transfer.
| Age for injection | Mouse strain | No. of mice | Survival rate (%) | Frequency of engrafted mice (%) |
Human CD45+ cells (%)* |
|---|---|---|---|---|---|
| Adult | NOG | 10 | 70 (7/10) | 100 (7/7) | 50.8 ± 17.2 |
| NR2G | 10 | 100 (10/10) | 100 (10/10) | 40.0 ± 12.4 | |
| NOD-scid | 9 | 55.6 (5/9) | 100 (5/5) | 43.4 ± 14.6 | |
| Newborn | NOG | 6 | 100 (6/6) | 100 (6/6) | 69.9 ± 4.5 |
| NR2G | 6 | 83.3 (5/6) | 100 (5/5) | 43.1 ± 9.9 | |
| NOD-scid | 5 | 40 (2/5) | 100 (2/2) | 12.3 ± 2.1 |
*Percentages of human CD45+ cells in mononuclaer cells of peripheral blood.